Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients
O Frank, B Brors, A Fabarius, L Li, M Haak, S Merk… - Leukemia, 2006 - nature.com
Although the selective tyrosine kinase inhibitor imatinib is successfully used in the treatment
of chronic myeloid leukemia (CML), inherent mechanisms confer primary resistance to …
of chronic myeloid leukemia (CML), inherent mechanisms confer primary resistance to …
[HTML][HTML] Correlation of Pharmacokinetic Data with Cytogenetic and Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic …
RA Larson, BJ Druker, F Guilhot, SG O'Brien… - Blood, 2006 - Elsevier
A total of 551 pts with newly diagnosed CML-CP received imatinib (IM) 400 mg orally once
daily as part of the IRIS study (O'Brien et al, NEJM 2003). We now summarize the correlation …
daily as part of the IRIS study (O'Brien et al, NEJM 2003). We now summarize the correlation …
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate
ME O'Dwyer, MJ Mauro, C Blasdel, M Farnsworth… - Blood, 2004 - ashpublications.org
We followed 141 patients treated with imatinib mesylate (> 300 mg) for chronicphase chronic
myelogenous leukemia (CML) following failure of treatment with interferon. During 12 …
myelogenous leukemia (CML) following failure of treatment with interferon. During 12 …
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic …
SK Sohn, SJ Oh, BS Kim, HM Ryoo… - Leukemia & …, 2011 - Taylor & Francis
To investigate the correlation of trough imatinib mesylate (IM) levels with cytogenetic or
molecular responses, we measured trough IM levels in patients with chronic myeloid …
molecular responses, we measured trough IM levels in patients with chronic myeloid …
[HTML][HTML] Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy
G Etienne, S Dulucq, FE Nicolini, S Morisset… - …, 2014 - ncbi.nlm.nih.gov
Sustained imatinib treatment in chronic myeloid leukemia patients can result in complete
molecular response allowing discontinuation without relapse. We set out to evaluate the …
molecular response allowing discontinuation without relapse. We set out to evaluate the …
Evaluation of residual disease and TKI duration are critical predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients
FE Nicolini, S Dulucq, L Boureau, P Cony-Makhoul… - Clinical Cancer …, 2019 - AACR
Purpose: Tyrosine kinase inhibitor (TKI) discontinuation is an emerging goal in chronic
myelogenous leukemia (CML) management and several studies have demonstrated the …
myelogenous leukemia (CML) management and several studies have demonstrated the …
[PDF][PDF] Hematological and molecular response evaluation of CML patients on imatinib
Abstract Background: The BCR-ABL tyrosine kinase is a well-validated therapeutic target in
Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase …
Chronic Myeloid Leukemia (CML). Imatinib mesylate (formerly STI-571), a tyrosine kinase …
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
S Picard, K Titier, G Etienne, E Teilhet, D Ducint… - Blood, 2007 - ashpublications.org
Using high-performance liquid chromatography–tandem mass spectrometry, we assessed
trough imatinib plasma levels in 68 patients with chronic myeloid leukemia (CML) who …
trough imatinib plasma levels in 68 patients with chronic myeloid leukemia (CML) who …
Discontinuation of imatinib therapy after achieving a molecular response
J Cortes, S O'Brien, H Kantarjian - Blood, 2004 - ashpublications.org
Imatinib has become standard therapy for patients with chronic myelogenous leukemia
(CML). A complete cytogenetic response can be achieved in 75% to 90% of patients treated …
(CML). A complete cytogenetic response can be achieved in 75% to 90% of patients treated …
Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia
Therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia (CML) is
an ongoing debate. We studied the influence of imatinib trough levels on therapeutic …
an ongoing debate. We studied the influence of imatinib trough levels on therapeutic …